US20030206301A1 - Portable system for detecting skin abnormalities based on characteristic autofluorescence - Google Patents

Portable system for detecting skin abnormalities based on characteristic autofluorescence Download PDF

Info

Publication number
US20030206301A1
US20030206301A1 US10/438,551 US43855103A US2003206301A1 US 20030206301 A1 US20030206301 A1 US 20030206301A1 US 43855103 A US43855103 A US 43855103A US 2003206301 A1 US2003206301 A1 US 2003206301A1
Authority
US
United States
Prior art keywords
light
image
optical
abnormality detection
detection system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/438,551
Inventor
Richard Cline
Pierre Leduc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xillix Technologies Corp
Original Assignee
Xillix Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xillix Technologies Corp filed Critical Xillix Technologies Corp
Priority to US10/438,551 priority Critical patent/US20030206301A1/en
Publication of US20030206301A1 publication Critical patent/US20030206301A1/en
Priority to US10/830,680 priority patent/US20040196463A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/44Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0088Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for oral or dental tissue

Definitions

  • the present invention relates to the detection of skin abnormalities and, more particularly, to the detection of cancerous or precancerous skin tissue using autofluorescence.
  • One technique that can aid a physician in the detection of cancerous or precancerous lesions is based on the difference in autofluorescence light produced by healthy and non-healthy tissue. All tissue will fluoresce or produce light within a well-defined range of wavelengths when excited. It is known that the autofluorescence light produced by healthy tissue has a spectral profile that differs from that produced by non-healthy tissue. A number of research groups have exploited this difference in the spectral profile by recording the wavelength spectrum of a single point. Although this provides interesting data, it is clinically difficult to use.
  • the present invention is a lightweight, hand-held skin abnormality detection imaging system including a source of excitation light which causes tissue under examination to produce autofluorescence light.
  • the autofluorescence light generated from the tissue under examination along with reference light is directed to a pair of optical channels that produce an image of the tissue under examination.
  • An optical combiner which preferably comprises a dichroic mirror, superimposes the images of the tissue to be viewed by a user.
  • the autofluorescence light received in one channel has a wavelength selected such that the autofluorescence intensity for healthy tissue differs from the autofluorescence intensity produced for diseased or suspect tissue.
  • the reference light comprises autofluorescence light, wherein the autofluorescence intensity for diseased tissue is substantially similar to the autofluorescence intensity for healthy tissue.
  • the reference light comprises reflected excitation light.
  • the reference light comprises light having wavelengths that differ from the wavelengths of the excitation light.
  • the combined superimposed output images may be viewed by a user or may be captured by an analog or digital camera.
  • these embodiments can all be implemented with monocular or binocular viewing.
  • FIG. 1 is a schematic block diagram of a first embodiment of a skin abnormality detection system according to the present invention that detects abnormalities by providing a monocular, false color view of the skin based on two detection wavelength bands of autofluorescence light;
  • FIG. 2 is an example of a combined color view produced by the present invention using a blue excitation filter, a first autofluorescence optical channel with a green emission filter and a green phosphor screen and a second autofluorescence optical channel with a red emission filter and red phosphor screen;
  • FIG. 3 is a schematic block diagram of another embodiment of a skin abnormality detection system according to the present invention that detects abnormalities by providing a binocular, false color view of the skin based on two detection wavelengths of autofluorescence light;
  • FIG. 4 is a schematic block diagram of yet another embodiment of a skin abnormality detection system according to the present invention that detects abnormalities by providing a camera which captures a false color image of the skin based on two detection wavelengths of autofluorescence light.
  • the present invention is a lightweight, hand-held system for detecting skin abnormalities based on the differences in autofluorescence light produced by healthy and diseased tissue.
  • a skin abnormality detection system 5 is made up of seven major subsystems: a light source 10 that produces excitation light that will cause a tissue sample 12 under examination to produce characteristic autofluorescence light.
  • An optical splitter 13 divides the fluorescence light received from the tissue sample 12 into two beams of different wavelengths. The first beam is directed into a first optical channel 14 that collects, amplifies, and images the light in one fluorescence wavelength band, and a second beam is directed into a second optical channel 15 that collects, amplifies, and images the light in a second fluorescence wavelength band.
  • An optical combiner 16 combines the images from the two optical channels 14 and 15 into one and presents the combined image the user's eye 19 .
  • the system 10 includes a control module 17 , and a power source 18 .
  • the system described above is a monocular viewer that produces a combined false color image that is made up of images from two fluorescence wavelength bands.
  • the power source 18 could be batteries or the AC line. In the preferred embodiment battery power is utilized for portability.
  • the light source 10 provides light of the required characteristics for exciting the tissue fluorescence. It consists of a power supply 21 , which is controlled by the control module 27 and which receives electrical power from power source 18 .
  • the power supply outputs electrical power of the appropriate characteristics to operate a lamp 22 .
  • the lamp which may be a xenon flash lamp, produces a broad spectrum output of visible light (e.g. white light).
  • the light is formed into a beam which uniformly illuminates the tissue 12 by a reflector 23 and the combination of image forming elements 24 and 25 (e.g. lenses). A region of collimated light is produced between the two lenses.
  • the region of collimated light provides optimal conditions for the placement of an optical band pass filter, excitation filter 26 , designed for incident light to be perpendicular to filter's surface.
  • the excitation filter characteristics are preferably selected such that the filter passes light of wavelengths utilized to excite fluorescence (typically 400 nm to 450 nm) and blocks light of other wavelengths.
  • the blocking by the filter in the wavelength bands where fluorescence is detected must be very good (i.e. in those bands, less than 1 in 10 5 of the light from the lamp should be able to pass through the filter).
  • the lamp 22 is operated in a pulsed mode similar to a camera flash; however, it could be on continuously.
  • the advantages of operating in the pulsed mode are that it allows the system to be utilized in an undarkened room and the power required is reduced so battery operation is possible.
  • the intensity and duration of the light (when pulsed) are controlled by the control module 17 as a means of adjusting the brightness of the image as detected by the user's eye 19 .
  • the result of illuminating the tissue 12 with excitation light is the emission of characteristic autofluorescence light 31 by the tissue. If the excitation light is in the blue portion of the spectrum, the emitted fluorescence typically spans wavelengths from the green to the red (470 nm to 700 nm).
  • the emitted autofluorescence light 31 is collected and split into two wavelength bands by the optical splitter 13 .
  • An image forming element (e.g. lens assembly) 41 in the optical splitter 13 collects the emitted fluorescence light and forms an image of the tissue at infinity. The image can be focused at infinity via focus mechanism 44 .
  • the light is directed onto a dichroic mirror 42 resulting in the autofluorescence light being split into two wavelength bands.
  • a portion of the light in one wavelength band passes straight through the dichroic mirror 42 and enters the first optical channel 14 .
  • the remaining light in the second wavelength band is reflected by the dichroic mirror 42 .
  • the dichroic mirror 42 will pass light having wavelengths less than 570 nm and will reflect light having wavelengths greater than 570 nm.
  • the light reflected by the dichroic mirror is again reflected by a mirror 43 into the second optical channel 15 .
  • the autofluorescence light that passes straight through the dichroic mirror 42 enters the first optical channel 14 .
  • autofluorescence light with wavelengths within a defined band is amplified and formed into an image.
  • the optical channel 14 consists of an emission filter 52 , a lens assembly 53 , an image intensifier 54 with phosphor screen 55 and power supply 56 .
  • Emission filter 52 passes only the autofluorescence light in a band of wavelengths near the maximum in the tissue spectral emission (typically 490 nm to 560 nm).
  • the emission filter 52 should have particularly good blocking characteristics for light in the wavelength band utilized for fluorescence excitation—typically less than 1 in 10 5 of the excitation light passes the emission filter 52 .
  • the lens 53 forms an image with the autofluorescence light on the input of the image intensifier 54 .
  • the image intensifier is a device that amplifies the light by a gain determined by a bias voltage that is supplied by power supply 56 .
  • the image intensifier produces an output image on a phosphor screen 55 (actually an integral part of the image intensifier).
  • the power supply 56 is controlled by a controller 71 within the control module 17 .
  • the controller 71 controls the output of the power supply 56 in such a way that the intensifier has the appropriate gain for the light input into the system and is protected from overexposure.
  • the image intensifier phosphor screen 55 preferably has a long persistence so that the amplified image would be visible for a few seconds.
  • the phosphor screen 55 would produce light of a specific wavelength band, for example green light mainly in the band 500 nm to 560 nm.
  • the light from the image on the phosphor screen 55 is input to the optical combiner 16 .
  • the second optical channel 15 consists of an emission filter 62 , a lens 63 , an image intensifier 64 with phosphor screen 65 and power supply 66 .
  • the second optical channel 15 is nearly identical to the first optical channel 14 except that the emission filter 62 is different than emission filter 52 in that filter 62 passes light of a different wavelength band (e.g. passes red light in the band 630 to 750 nm).
  • the phosphor screen 65 produces light of a different wavelength (e.g.
  • the gain of the image intensifier 64 as set by the controller 71 and power supply 66 may be different than the gain of image intensifier 54 .
  • the image formed on phosphor screen 65 is from a different autofluorescence band and may be of different brightness.
  • the light from the image on phosphor screen 65 is supplied as an input to the optical combiner 16 .
  • the optical combiner 16 consists of a lens 81 , a lens 82 , a dichroic mirror 83 , a mirror 84 , a lens 85 , and a light sensor 86 .
  • the lens 81 collects light from the image on phosphor screen 55 , and in combination with lens 85 relays the image from the phosphor screen to the user's eye 19 .
  • Light from the image on phosphor screen 55 in one wavelength band (e.g. green light) passes straight through dichroic mirror 83 .
  • the dichroic mirror 83 has, for example, characteristics such that light at wavelengths shorter than 570 nm passes straight through and light at wavelengths longer than 570 nm is reflected.
  • Lens 82 collects light from the second optical channel in a second wavelength band (e.g. red light) from the image on phosphor screen 65 .
  • Lens 82 in combination with lens 85 relays the image from phosphor screen 65 to the user's eye 19 .
  • the light from phosphor screen 65 is reflected both by mirror 84 and dichroic mirror 83 . This results, in combination with the image from phosphor screen 55 that passed straight through the dichroic mirror 83 , in the formation of a combined image a the user's eye 19 made up of the images from phosphor screens 55 and 65 .
  • the magnifications of lenses 81 and 82 are chosen so that the images from phosphor screens 55 and 65 are the same size at the user's eye, even though the optical path lengths are different.
  • the control module 17 consists of the controller 71 , acquire image pushbutton 72 , and brightness adjustment knob 73 .
  • the controller 71 contains circuitry to control the light source power supply 21 and image intensifier power supplies 56 , 66 , as well as, circuitry that measures the output voltage of light sensor 86 .
  • the acquire image pushbutton 72 is activated by the user to signal to the controller to start the image acquisition sequence when the device is operated in a pulsed mode.
  • the brightness adjustment knob 73 is utilized by the user to communicate an adjustable reference point for the brightness of the image to the controller.
  • the brightness of the image seen by the user is automatically controlled by the controller 71 based on a combination of measurement of light intensity by the light sensor 86 , the reference brightness from the brightness adjustment knob 73 , and stored image intensifier calibration characteristics.
  • the controller 71 utilizes this information to control the light source intensity and duration, as well as the gain of image intensifiers 54 and 64 .
  • the control algorithm is designed to operate at the maximum possible light source intensity and pulse duration and minimum intensifier gains. The control algorithm first adjusts the light source intensity and duration (when pulsed) to achieve the desired brightness.
  • the algorithm then adjusts the gain of image intensifier 54 to achieve the target brightness and then adjusts the gain of image intensifier 64 in such a way that the ratio of the gain of intensifier 54 to the gain of intensifier 64 is constant, based on the calibration parameters. In this way, the color of the combined image is made to be independent of the brightness of the image and independent of the distance between the tissue and the device.
  • a second embodiment of the skin abnormality detection system is also based on FIG. 1.
  • the architecture of the system is the same as the first embodiment and a combined view similar to that shown in FIG. 2 is produced, but a different principle of operation is utilized, necessitating different implementation details.
  • an image is produced by overlaying images from two different wavelength bands of autofluorescence light.
  • the color of the composite image resulting from the first embodiment depends on the health of the tissue, because the intensity of the autofluorescence light forming one of the images (green) is known to be a strong function of the health of the tissue, whereas the intensity of autofluorescence light forming the second image (red) depends weakly on the health of the tissue.
  • a composite image is formed based on one image from the wavelength band of autofluorescence light that is a strong function of the health of the tissue (green), and one image formed from reflected excitation light (blue).
  • the color of the combined image depends on the health of the tissue, because the intensity of the autofluorescence light forming one image utilized in the composite varies depending on the health of the tissue, whereas the intensity of the reflected light forming the second image of the composite depends only weakly on the health of the tissue.
  • the implementation details for the second embodiment are different from those of the first embodiment in the following ways:
  • the emission filter 62 for the second optical channel 15 transmits light reflected from the tissue of the same wavelength band as the light emitted by the light source (e.g. 400 nm to 450 nm).
  • the image intensifier 64 in the second optical channel 15 of the second embodiment does not need to amplify the light as much and can be of lower quality.
  • dichroic mirror 42 is designed to transmit light with shorter wavelengths, for example ⁇ 570 nm in the first embodiment, there is no need to utilize a different dichroic mirror for the second embodiment.
  • dichroic mirrors typically reflect 5% of the incident light in region they transmit, so the dichroic mirror 42 specified in the first embodiment can be utilized to reduce the intensity of the light reflected from the tissue going into the second optical channel 15 .
  • a dichroic mirror that transmits in the green and reflects in the blue e.g. reflects wavelengths ⁇ 470 nm and transmits wavelengths>470 nm
  • a neutral density filter or low gain image intensifier can be utilized.
  • a third embodiment of the skin abnormality detection system is also based on the architecture of FIG. 1 and produces a combined view similar to that shown in FIG. 2.
  • the third embodiment utilizes the same principle of operation as the second embodiment, but differs in the implementation details.
  • a combined image is formed from the combination of a fluorescence image and a reflected image. The difference is that instead of utilizing the excitation light as the source of light for the reflected image, the light source 10 outputs light expressly for the purpose of producing a reflected image, at a wavelength that is longer than that utilized for the detection of fluorescence.
  • the excitation filter 26 in the third embodiment has two passbands, one passing short wavelengths for fluorescence excitation (for example 400 nm to 450 nm), and one passing longer wavelengths for the reflected image (for example 630 nm to 700 nm).
  • the filter preferably has very good blocking characteristics in the wavelength region where fluorescence is detected (e.g. less than 10 ⁇ 5 of the incident light should be transmitted between 470 nm and 600 nm).
  • the emission filter 62 passes light in the longer wavelength band which is used for the reflected image (for example 630 nm to 700 nm).
  • This filter 62 should have good blocking of the light in the excitation wavelength band (400 nm to 450 nm in this example).
  • the emission filter 52 must, in addition to the characteristics described for the first embodiment, also have good blocking of light in the band used for the reflect image (for example, in the band 630 nm to 700 nm less than 10 ⁇ 5 of the light should pass the filter).
  • the balance of the system is similar to that of the second embodiment.
  • FIG. 3 A fourth embodiment of the skin abnormality detection system according to the present invention is shown in FIG. 3.
  • the fourth embodiment is a viewer that produces a combined, binocular image based on images either from two wavelength bands of emitted autofluorescence light, or from one wavelength band of emitted autofluorescence light and one wavelength band of reflected light.
  • the system described in the fourth embodiment can be obtained by combining two of the systems (i.e., one for each eye) described in one of the first three embodiments to obtain a binocular view.
  • the imaging system 100 includes a power source 102 , a control module 104 and a light source 106 that supplies light to excite a tissue sample 108 to produce autofluorescence light.
  • a left imaging system 5 L provides a superimposed autofluorescence image to a viewer's left eye in the same manner as the system shown in FIG. 1 and described above.
  • An imaging system SR provides a superimposed autofluorescence image for a viewer's right eye in the same manner as the system 5 shown in FIG. 1.
  • a fifth embodiment of the skin abnormality detection system is shown in FIG. 4.
  • the fifth embodiment is an optical system that produces a combined image based on images from two wavelength bands of emitted autofluorescence light.
  • the fifth embodiment is similar to the first embodiment, except that it is intended to be utilized with an instant camera or a digital camera instead of the user's eye.
  • a combined view, similar to that shown in FIG. 2 is recorded and displayed by means of the camera.
  • the fifth embodiment of a skin abnormality detection system is made up of eight major subsystems: a light source 10 that produces excitation light that will cause the tissue 12 under examination to produce characteristic autofluorescence light, an optical splitter 13 that divides the fluorescence light received from the tissue into two beams, a first optical channel 14 that collects, amplifies, and images the light in one fluorescence wavelength band, a second optical channel IS that collects, amplifies, and images the light in a second fluorescence wavelength band, an optical combiner 16 that combines the images from the two fluorescence optical channels into one and presents the combined image to a digital or instant camera 120 which records the image for viewing, a control module 17 , and a power source 18 .
  • a light source 10 that produces excitation light that will cause the tissue 12 under examination to produce characteristic autofluorescence light
  • an optical splitter 13 that divides the fluorescence light received from the tissue into two beams
  • a first optical channel 14 that collects, amplifies, and images the light in one fluor
  • the power source 18 could be batteries or the AC line. In the preferred embodiment, battery power is utilized for portability.
  • the light source 10 provides light of the required characteristics for exciting the tissue fluorescence. It consists of a power supply 21 which is controlled by the control module 17 and which receives electrical power from power source 18 .
  • the power supply outputs electrical power of the appropriate characteristics to operate lamp 22 .
  • the lamp which may be a xenon flash lamp, produces a broad spectrum output of visible light (e.g. white light).
  • the light is formed into a beam onto the tissue 12 by reflector 23 and the combination of image forming elements 24 and 25 (e.g. lenses). In addition to forming a beam, a region of collimated light is produced between the two lenses that provides optimal conditions for the placement of an optical band pass filter, excitation filter 26 .
  • This filter 26 is designed for incident light to be perpendicular to the filter surface.
  • the excitation filter 16 characteristics are such that the filter passes light of wavelengths utilized to excite fluorescence (typically 400 nm to 450 nm) and blocks light of other wavelengths. It is important that the filter block light in the wavelength bands where fluorescence is detected (i.e. in those bands no more than 1 in 10 5 of the light from the lamp can pass the filter).
  • the lamp 22 is operated in a pulsed mode similar to a camera flash.
  • the advantages of operating in the pulsed mode are that it allows the system to be utilized in an undarkened room and the power required is reduced so battery operation is possible.
  • the intensity and duration of the light (when pulsed) are controlled by the control module 17 as a means of adjusting the brightness of the image as detected by the camera 120 .
  • the result of illuminating the tissue 12 with excitation light is the emission of characteristic autofluorescence light 31 by the tissue. If the excitation light is in the blue, the emitted fluorescence typically spans wavelengths from the green to the red (470 nm to 700 nm).
  • the emitted autofluorescence light 31 is collected and split into two wavelength bands by the optical splitter 13 .
  • An image forming element (e.g. lens) 41 in the optical splitter collects the emitted fluorescence light and forms an image of the tissue.
  • the position of the lens 41 can be moved via focus mechanism 44 to focus the image.
  • the light is directed onto a dichroic mirror 42 resulting in the autofluorescence light being split into two wavelength bands.
  • a portion of the light in one wavelength band passes straight through the dichroic mirror and enters the first optical channel 14 .
  • the remaining light in the second wavelength band is reflected by the dichroic mirror 42 .
  • the dichroic mirror 42 will pass light having wavelengths less than 570 nm and will reflect light having wavelengths greater than 570 nm.
  • the light reflected by the dichroic mirror is again reflected by a mirror 43 into the second optical channel 15 .
  • the autofluorescence light that passes straight through the dichroic mirror 42 enters the first optical channel 14 .
  • autofluorescence light with wavelengths within a defined band is amplified and formed into an image.
  • the optical channel 14 consists of a lens 53 , an emission filter 52 , an image intensifier 54 with phosphor screen 55 and power supply 56 .
  • the lens 53 forms an image at an infinite distance to collimate the light. This results in an optimum location for the emission filter 52 that is designed to filter incident light perpendicular to the filter's surface.
  • Emission filter 52 passes only the autofluorescence light in a band of wavelengths near the maximum in the tissue spectral emission (typically 490 nm to 560 nm).
  • the emission filter preferably has good blocking characteristics for light in the wavelength band utilized for fluorescence excitation. Typically less than 1 in 10 5 of the excitation light passes the emission filter.
  • the lens 53 forms an image with the autofluorescence light on the input of the image intensifier 54 .
  • the image intensifier amplifies the incoming light by a gain determined by a bias voltage supplied by power supply 56 .
  • the image intensifier produces an output image on phosphor screen 55 .
  • the power supply 56 is controlled by the control module 17 .
  • the control module controls the output of the power supply in such a way that the intensifier has the appropriate gain for the light input to the system.
  • the image intensifier phosphor screen 55 has a persistence of at least a few milliseconds, and produces light of a specific wavelength, for example green light mainly in the band 500 nm to 560 nm.
  • the light from the image on the phosphor screen is input to the optical combiner 16 .
  • the second optical channel 15 consists of a lens 63 , an emission filter 62 , an image intensifier 64 with phosphor screen 65 and power supply 66 .
  • the second optical channel 15 is nearly identical to the first optical channel 14 except that the emission filter 62 is different than emission filter 52 in that filter 62 passes light of a different wavelength band (e.g. red light in the band 630 to 750 nm), phosphor screen 65 produces light of different wavelength (e.g.
  • the gain of the image intensifier 64 as set by controller 71 and power supply 66 may be different than the gain of image intensifier 54 .
  • the image formed on phosphor screen 65 is from a different autofluorescence band and may be of different brightness.
  • the light from the image on phosphor screen 65 is input to the optical combiner 16 .
  • the optical combiner 16 consists of lens 81 , lens 82 , dichroic mirror 83 , mirror 84 and lens 85 .
  • Lens 81 collects light from the image on phosphor screen 55 , and in combination with lens 85 relays the image from the phosphor screen to the camera's 120 optical system.
  • Light from the image on phosphor screen 55 in one wavelength band (e.g. green light) passes straight through dichroic mirror 83 .
  • the dichroic mirror 83 has, for example, characteristics such that light at wavelengths shorter than 570 nm passes straight through and light at wavelengths longer than 570 nm is reflected.
  • Lens 82 collects light from the second optical channel in a second wavelength band (e.g.
  • Lens 82 in combination with lens 85 relays the image from phosphor screen 65 to the camera's 120 optical system.
  • the light from phosphor screen 65 is reflected both by mirror 84 and dichroic mirror 83 .
  • the magnifications of lenses 81 and 82 are chosen so that the images from phosphor screens 55 and 65 are the same size at the camera's optical system, even though the optical path lengths are different.
  • the fifth embodiment of a skin abnormality detection system attaches to a digital or instant camera 120 by means of the camera lens mount 122 , or by means of a screw in filter mount on the camera's lens.
  • the control module 17 consists of a controller 71 , and brightness adjustment knob 72 .
  • the controller 71 contains circuitry to control the light source power supply and image intensifier power supplies.
  • the shutter button 123 on the camera is activated by the user to start the image acquisition sequence.
  • the camera sends a signal to the controller 71 through the flash synchronization output jack 121 indicating that image acquisition is to start and related to the image brightness.
  • the controller makes use of this signal in controlling the light source power supply and image intensifier power supplies as described below.
  • the brightness adjustment knob 72 is utilized by the user to communicate an adjustable reference point for the brightness of the image to the controller.
  • the brightness of the image as seen by the user is automatically controlled by the controller 71 based on a combination of measurement of light intensity by the camera light meter, the reference brightness from the brightness adjustment knob 72 , and stored image intensifier calibration characteristics.
  • the controller 71 utilizes this information to control the light source intensity and duration, as well as the gain of image intensifiers 54 and 64 .
  • the image intensifiers, controlled through their power supplies, are turned on by the controller 71 only during the period that the light source outputs light, plus an additional period while the fluorescence decays (typically 100 microseconds).
  • the camera's shutter is opened for a time much longer than the duration of the light source output (typically ⁇ fraction (1/125) ⁇ of a second).
  • control algorithm In order to achieve the best image quality, the control algorithm is designed to operate at the maximum possible light source intensity and pulse duration and minimum intensifier gains.
  • the control algorithm first adjusts the light source intensity and duration to achieve the desired brightness as indicated by the camera light meter. Following this the algorithm adjusts the gain of image intensifier 54 as further required to achieve the desired brightness and then adjusts the gain of image intensifier 64 in such a way that the ratio of the gain of intensifier 54 to the gain of intensifier 64 is constant, based on the calibration parameters. In this way, the color of the combined image is made to be independent of the brightness of the image and independent of the distance between the tissue and the device.
  • a sixth embodiment of the skin abnormality detection system is also based on the embodiment shown in FIG. 4.
  • the architecture of the system is the same as the fifth embodiment and a combined view similar to that shown in FIG. 2 is produced, but a different principle of operation is utilized, necessitating different implementation details.
  • the sixth embodiment is similar to the second embodiment except that the sixth embodiment utilizes a camera to store the image whereas the second embodiment is a viewer.
  • an image is produced by overlaying images from two different wavelength bands of autofluorescence light.
  • the color of the composite image resulting from the first embodiment depends on the health of the tissue, because the intensity of the autofluorescence light forming one of the images (green) is known to be a strong function of the health of the tissue, whereas the intensity of autofluorescence light forming the second image (red) depends weakly on the health of the tissue.
  • a composite image is formed based on one image from the wavelength band of autofluorescence light that is a strong function of the health of the tissue (green), and one image formed from reflected excitation light (blue).
  • the color of the combined image depends on the health of the tissue, because the intensity of the autofluorescence light forming one image utilized in the composite varies depending on the health of the tissue, whereas the intensity of the reflected light forming the second image of the composite depends only weakly on the health of the tissue.
  • the emission filter 62 for the second optical channel transmits light reflected from the tissue of the same wavelength band as the light emitted by the light source (e.g. 400 nm to 450 nm).
  • the image intensifier 64 in the second optical channel 15 of the second embodiment does not need to amplify the light as much and can be of lower quality.
  • dichroic mirror 42 is designed to transmit light with shorter wavelengths, for example ⁇ 570 nm in the first embodiment, there is no need to utilize a different dichroic mirror in this embodiment.
  • dichroic mirrors reflect 5% of the incident light in region they transmit, so the dichroic mirror as specified in the fifth embodiment can be utilized to reduce the intensity of the light reflected from the tissue going into the second optical channel 15 .
  • a dichroic mirror that transmits in the green and reflects in the blue e.g. reflects wavelengths ⁇ 470 nm and transmits wavelengths>470 nm
  • a neutral density filter or low gain image intensifier can be utilized.
  • a seventh embodiment of the skin abnormality detection system is also based on the architecture of FIG. 4 and produces a combined view similar to that shown in FIG. 2.
  • the seventh embodiment utilizes the same principle of operation as the sixth embodiment, but differs in the implementation details.
  • the seventh embodiment is similar to the third embodiment except that the seventh embodiment utilizes a camera to store the image whereas the third embodiment is a viewer.
  • a combined image is formed from the combination of a fluorescence image and a reflected image. The difference is that instead of utilizing the excitation light as the source of light for the reflected image, the light source 10 outputs light expressly for the purpose of producing a reflected image, at a wavelength longer than that utilized for the detection of fluorescence.
  • the excitation filter 26 in the seventh embodiment light source has two passbands, one passing short wavelengths for fluorescence excitation (for example 400 nm to 450 nm), and one passing longer wavelengths for the reflected image (for example 630 nm to 700 nm).
  • the filter preferably has very good blocking characteristics in the wavelength region where fluorescence is detected (e.g. less than 10 ⁇ 5 of the incident light should be transmitted between 470 nm and 600 nm).
  • the emission filter 62 must also pass light in the longer wavelength band which is used for the reflected image (for example 630 nm to 700 nm).
  • This filter should have good blocking of the light in the excitation wavelength band (400 nm to 450 nm in this example).
  • the emission filter 52 must, in addition to the characteristics described for the fifth embodiment, also have good blocking of light in the band used for the reflect image (for example, in the band 630 nm to 700 nm less than 10 ⁇ 5 of the light should pass the filter).
  • the balance of the system is similar to that of the sixth embodiment.
  • the present invention is not limited to the detection of skin cancer but can be used to detect other types of lesions that exhibit variations in autofluorescence intensities.
  • the invention may also be utilized in internal organs such as the mouth or during surgical procedures.
  • the abnormality detection may also be coupled to a scope, such as an endoscope or laproscope, used in the medical field to examine internal tissues and organs.
  • the embodiments described may also be used with tissue where photodynamic agents, which enhance the fluorescence response, have been introduced.
  • the detection system may be used not only on skin, but also on other surfaces, such as the detection of abnormalities on plants, and the detection of contaminants on non-living surfaces, such as surgical tools or food. It is, therefore, intended that the scope of the invention be determined from the following claims and equivalents thereto.

Abstract

A lightweight hand-held skin abnormality detection system includes a source of excitation light that causes tissue under examination to produce fluorescence light. The fluorescence light produced along with the beam of reference light is provided to a beam splitter which divides the fluorescence light and the reference light into separate optical channels. Each optical channel produces an image of the tissue under examination. A passive optical combiner superimposes the image produced by each optical channel for viewing by a user.

Description

    FIELD OF THE INVENTION
  • The present invention relates to the detection of skin abnormalities and, more particularly, to the detection of cancerous or precancerous skin tissue using autofluorescence. [0001]
  • BACKGROUND OF THE INVENTION
  • Whether due to increased awareness or a variety of environmental factors, the incidence of detected cases of skin cancer is increasing. Because most skin cancers are curable if treated early, there is an increased emphasis on the detection of malignant or premalignant skin tissue. The majority of skin cancers are detected based on a visual observation of a patient's skin under white light by a trained dermatologist. However, the success of such a method relies heavily on the ability of the physician to distinguish healthy skin from a potentially malignant lesion. [0002]
  • One technique that can aid a physician in the detection of cancerous or precancerous lesions is based on the difference in autofluorescence light produced by healthy and non-healthy tissue. All tissue will fluoresce or produce light within a well-defined range of wavelengths when excited. It is known that the autofluorescence light produced by healthy tissue has a spectral profile that differs from that produced by non-healthy tissue. A number of research groups have exploited this difference in the spectral profile by recording the wavelength spectrum of a single point. Although this provides interesting data, it is clinically difficult to use. [0003]
  • One system for detecting cancerous tissue based on differences in autofluorescence light is described in U.S. Pat. No. 5,507,287, which is assigned to the Xillix Technologies Corporation of Richmond, B.C., Canada, the assignee of the present invention. However, this and similar systems generally require a computer monitor and image processing equipment in order to produce images of suspect tissue and are not portable enough to be used outside a hospital. In addition, these systems are relatively expensive and require significant amounts of energy to operate. [0004]
  • A lightweight, portable system for the detection of autofluorescence light of the skin is described in PCT application PCT/CA97/00919, entitled “Fluorescence Scope System for Dermatologic Diagnosis.” However, depending on the embodiment, this device either lacks sensitivity due to the lack of light amplification, or is difficult to use due to the requirement for the user to mentally combine images of different colors presented to each eye. [0005]
  • To increase the ability of medical personnel to perform screening tests on greater numbers of patients, there is a need for a low-cost, lightweight, portable cancer detection system that can aid physicians in the detection of potentially malignant lesions based on differences in the autofluorescence light produced by healthy and suspect tissue. [0006]
  • SUMMARY OF THE INVENTION
  • The present invention is a lightweight, hand-held skin abnormality detection imaging system including a source of excitation light which causes tissue under examination to produce autofluorescence light. The autofluorescence light generated from the tissue under examination along with reference light is directed to a pair of optical channels that produce an image of the tissue under examination. An optical combiner, which preferably comprises a dichroic mirror, superimposes the images of the tissue to be viewed by a user. [0007]
  • In one embodiment of the invention, the autofluorescence light received in one channel has a wavelength selected such that the autofluorescence intensity for healthy tissue differs from the autofluorescence intensity produced for diseased or suspect tissue. The reference light comprises autofluorescence light, wherein the autofluorescence intensity for diseased tissue is substantially similar to the autofluorescence intensity for healthy tissue. In another embodiment of the invention, the reference light comprises reflected excitation light. In yet another embodiment of the invention, the reference light comprises light having wavelengths that differ from the wavelengths of the excitation light. [0008]
  • The combined superimposed output images may be viewed by a user or may be captured by an analog or digital camera. For viewing by a user, these embodiments can all be implemented with monocular or binocular viewing.[0009]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein: [0010]
  • FIG. 1 is a schematic block diagram of a first embodiment of a skin abnormality detection system according to the present invention that detects abnormalities by providing a monocular, false color view of the skin based on two detection wavelength bands of autofluorescence light; [0011]
  • FIG. 2 is an example of a combined color view produced by the present invention using a blue excitation filter, a first autofluorescence optical channel with a green emission filter and a green phosphor screen and a second autofluorescence optical channel with a red emission filter and red phosphor screen; [0012]
  • FIG. 3 is a schematic block diagram of another embodiment of a skin abnormality detection system according to the present invention that detects abnormalities by providing a binocular, false color view of the skin based on two detection wavelengths of autofluorescence light; and [0013]
  • FIG. 4 is a schematic block diagram of yet another embodiment of a skin abnormality detection system according to the present invention that detects abnormalities by providing a camera which captures a false color image of the skin based on two detection wavelengths of autofluorescence light.[0014]
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
  • The present invention is a lightweight, hand-held system for detecting skin abnormalities based on the differences in autofluorescence light produced by healthy and diseased tissue. [0015]
  • As shown in FIG. 1, a skin [0016] abnormality detection system 5 according one embodiment of the present invention is made up of seven major subsystems: a light source 10 that produces excitation light that will cause a tissue sample 12 under examination to produce characteristic autofluorescence light. An optical splitter 13 divides the fluorescence light received from the tissue sample 12 into two beams of different wavelengths. The first beam is directed into a first optical channel 14 that collects, amplifies, and images the light in one fluorescence wavelength band, and a second beam is directed into a second optical channel 15 that collects, amplifies, and images the light in a second fluorescence wavelength band. An optical combiner 16 combines the images from the two optical channels 14 and 15 into one and presents the combined image the user's eye 19. In addition, the system 10 includes a control module 17, and a power source 18. The system described above is a monocular viewer that produces a combined false color image that is made up of images from two fluorescence wavelength bands.
  • The [0017] power source 18 could be batteries or the AC line. In the preferred embodiment battery power is utilized for portability.
  • The [0018] light source 10 provides light of the required characteristics for exciting the tissue fluorescence. It consists of a power supply 21, which is controlled by the control module 27 and which receives electrical power from power source 18. The power supply outputs electrical power of the appropriate characteristics to operate a lamp 22. The lamp, which may be a xenon flash lamp, produces a broad spectrum output of visible light (e.g. white light). The light is formed into a beam which uniformly illuminates the tissue 12 by a reflector 23 and the combination of image forming elements 24 and 25 (e.g. lenses). A region of collimated light is produced between the two lenses. The region of collimated light provides optimal conditions for the placement of an optical band pass filter, excitation filter 26, designed for incident light to be perpendicular to filter's surface. The excitation filter characteristics are preferably selected such that the filter passes light of wavelengths utilized to excite fluorescence (typically 400 nm to 450 nm) and blocks light of other wavelengths. The blocking by the filter in the wavelength bands where fluorescence is detected must be very good (i.e. in those bands, less than 1 in 105 of the light from the lamp should be able to pass through the filter).
  • Typically, the [0019] lamp 22 is operated in a pulsed mode similar to a camera flash; however, it could be on continuously. The advantages of operating in the pulsed mode are that it allows the system to be utilized in an undarkened room and the power required is reduced so battery operation is possible. The intensity and duration of the light (when pulsed) are controlled by the control module 17 as a means of adjusting the brightness of the image as detected by the user's eye 19.
  • The result of illuminating the [0020] tissue 12 with excitation light is the emission of characteristic autofluorescence light 31 by the tissue. If the excitation light is in the blue portion of the spectrum, the emitted fluorescence typically spans wavelengths from the green to the red (470 nm to 700 nm). The emitted autofluorescence light 31 is collected and split into two wavelength bands by the optical splitter 13. An image forming element (e.g. lens assembly) 41 in the optical splitter 13 collects the emitted fluorescence light and forms an image of the tissue at infinity. The image can be focused at infinity via focus mechanism 44. The light is directed onto a dichroic mirror 42 resulting in the autofluorescence light being split into two wavelength bands. A portion of the light in one wavelength band passes straight through the dichroic mirror 42 and enters the first optical channel 14. The remaining light in the second wavelength band is reflected by the dichroic mirror 42. Typically, the dichroic mirror 42 will pass light having wavelengths less than 570 nm and will reflect light having wavelengths greater than 570 nm. The light reflected by the dichroic mirror is again reflected by a mirror 43 into the second optical channel 15.
  • As mentioned previously, the autofluorescence light that passes straight through the [0021] dichroic mirror 42 enters the first optical channel 14. In this optical channel, autofluorescence light with wavelengths within a defined band is amplified and formed into an image. The optical channel 14 consists of an emission filter 52, a lens assembly 53, an image intensifier 54 with phosphor screen 55 and power supply 56. Emission filter 52 passes only the autofluorescence light in a band of wavelengths near the maximum in the tissue spectral emission (typically 490 nm to 560 nm). The emission filter 52 should have particularly good blocking characteristics for light in the wavelength band utilized for fluorescence excitation—typically less than 1 in 105 of the excitation light passes the emission filter 52. The lens 53 forms an image with the autofluorescence light on the input of the image intensifier 54. The image intensifier is a device that amplifies the light by a gain determined by a bias voltage that is supplied by power supply 56. The image intensifier produces an output image on a phosphor screen 55 (actually an integral part of the image intensifier). The power supply 56 is controlled by a controller 71 within the control module 17. The controller 71 controls the output of the power supply 56 in such a way that the intensifier has the appropriate gain for the light input into the system and is protected from overexposure. The image intensifier phosphor screen 55 preferably has a long persistence so that the amplified image would be visible for a few seconds. The phosphor screen 55 would produce light of a specific wavelength band, for example green light mainly in the band 500 nm to 560 nm. The light from the image on the phosphor screen 55 is input to the optical combiner 16.
  • As mentioned previously, the autofluorescence light that is reflected by the [0022] dichroic mirror 42 and mirror. 43 in the optical splitter 13 enters into the second optical channel 15. The second optical channel 15 consists of an emission filter 62, a lens 63, an image intensifier 64 with phosphor screen 65 and power supply 66. The second optical channel 15 is nearly identical to the first optical channel 14 except that the emission filter 62 is different than emission filter 52 in that filter 62 passes light of a different wavelength band (e.g. passes red light in the band 630 to 750 nm). The phosphor screen 65 produces light of a different wavelength (e.g. produces red light in the band 620 nm to 700 nm) than the phosphor screen 55 does with long persistence, and the gain of the image intensifier 64 as set by the controller 71 and power supply 66 may be different than the gain of image intensifier 54. As a result of these differences, the image formed on phosphor screen 65 is from a different autofluorescence band and may be of different brightness. The light from the image on phosphor screen 65 is supplied as an input to the optical combiner 16.
  • The [0023] optical combiner 16 consists of a lens 81, a lens 82, a dichroic mirror 83, a mirror 84, a lens 85, and a light sensor 86. The lens 81 collects light from the image on phosphor screen 55, and in combination with lens 85 relays the image from the phosphor screen to the user's eye 19. Light from the image on phosphor screen 55 in one wavelength band (e.g. green light) passes straight through dichroic mirror 83. The dichroic mirror 83 has, for example, characteristics such that light at wavelengths shorter than 570 nm passes straight through and light at wavelengths longer than 570 nm is reflected. Lens 82 collects light from the second optical channel in a second wavelength band (e.g. red light) from the image on phosphor screen 65. Lens 82, in combination with lens 85 relays the image from phosphor screen 65 to the user's eye 19. The light from phosphor screen 65 is reflected both by mirror 84 and dichroic mirror 83. This results, in combination with the image from phosphor screen 55 that passed straight through the dichroic mirror 83, in the formation of a combined image a the user's eye 19 made up of the images from phosphor screens 55 and 65. The magnifications of lenses 81 and 82 are chosen so that the images from phosphor screens 55 and 65 are the same size at the user's eye, even though the optical path lengths are different.
  • In addition to passing straight through [0024] dichroic mirror 83, a small proportion of the light from phosphor screen 55 is reflected by the dichroic mirror (typically 5%) onto sensor 86. This light is converted into an electrical signal proportional to the light amplitude, which is measured by the control module 17.
  • The control module [0025] 17 consists of the controller 71, acquire image pushbutton 72, and brightness adjustment knob 73. The controller 71 contains circuitry to control the light source power supply 21 and image intensifier power supplies 56, 66, as well as, circuitry that measures the output voltage of light sensor 86. The acquire image pushbutton 72 is activated by the user to signal to the controller to start the image acquisition sequence when the device is operated in a pulsed mode.
  • The brightness adjustment knob [0026] 73 is utilized by the user to communicate an adjustable reference point for the brightness of the image to the controller. The brightness of the image seen by the user is automatically controlled by the controller 71 based on a combination of measurement of light intensity by the light sensor 86, the reference brightness from the brightness adjustment knob 73, and stored image intensifier calibration characteristics. The controller 71 utilizes this information to control the light source intensity and duration, as well as the gain of image intensifiers 54 and 64. In order to achieve the best image quality, the control algorithm is designed to operate at the maximum possible light source intensity and pulse duration and minimum intensifier gains. The control algorithm first adjusts the light source intensity and duration (when pulsed) to achieve the desired brightness. The algorithm then adjusts the gain of image intensifier 54 to achieve the target brightness and then adjusts the gain of image intensifier 64 in such a way that the ratio of the gain of intensifier 54 to the gain of intensifier 64 is constant, based on the calibration parameters. In this way, the color of the combined image is made to be independent of the brightness of the image and independent of the distance between the tissue and the device.
  • Using the [0027] system 5 described above, two images of different color and brightness originating from two autofluorescence wavelength bands are overlaid for interpretation by the user as illustrated in FIG. 2. The color of the resulting combined image depends on the degree of abnormality of the tissue. The spectral characteristics of autofluorescence light emitted by the tissue depend on the degree of abnormality. Typically the autofluorescence light emission of abnormal tissue is different in the green portion of the spectrum compared to normal tissue. In contrast, the autofluorescence light emission in the red portion of the spectrum is essentially unchanged when comparing abnormal and normal tissue. As a result, the brightness of the green component of the combined image varies, depending on the degree of tissue abnormality. Tissue with a degree of abnormality appears a different shade (redder or greener) than normal tissue. Typically, users can easily discern subtle color differences indicative of abnormal tissue, especially when one area in the field of view is different than the rest.
  • A second embodiment of the skin abnormality detection system is also based on FIG. 1. The architecture of the system is the same as the first embodiment and a combined view similar to that shown in FIG. 2 is produced, but a different principle of operation is utilized, necessitating different implementation details. In the first embodiment, an image is produced by overlaying images from two different wavelength bands of autofluorescence light. The color of the composite image resulting from the first embodiment depends on the health of the tissue, because the intensity of the autofluorescence light forming one of the images (green) is known to be a strong function of the health of the tissue, whereas the intensity of autofluorescence light forming the second image (red) depends weakly on the health of the tissue. In the second embodiment, a composite image is formed based on one image from the wavelength band of autofluorescence light that is a strong function of the health of the tissue (green), and one image formed from reflected excitation light (blue). As in the first embodiment, the color of the combined image depends on the health of the tissue, because the intensity of the autofluorescence light forming one image utilized in the composite varies depending on the health of the tissue, whereas the intensity of the reflected light forming the second image of the composite depends only weakly on the health of the tissue. [0028]
  • The implementation details for the second embodiment are different from those of the first embodiment in the following ways: The [0029] emission filter 62 for the second optical channel 15 transmits light reflected from the tissue of the same wavelength band as the light emitted by the light source (e.g. 400 nm to 450 nm). In addition, because the reflected light is of much stronger intensity than the fluorescence light utilized in the first embodiment, the image intensifier 64 in the second optical channel 15 of the second embodiment does not need to amplify the light as much and can be of lower quality. Note that, although dichroic mirror 42 is designed to transmit light with shorter wavelengths, for example <570 nm in the first embodiment, there is no need to utilize a different dichroic mirror for the second embodiment. This is because dichroic mirrors typically reflect 5% of the incident light in region they transmit, so the dichroic mirror 42 specified in the first embodiment can be utilized to reduce the intensity of the light reflected from the tissue going into the second optical channel 15. Alternatively, a dichroic mirror that transmits in the green and reflects in the blue (e.g. reflects wavelengths<470 nm and transmits wavelengths>470 nm) in conjunction with a neutral density filter or low gain image intensifier can be utilized.
  • Like the second embodiment, a third embodiment of the skin abnormality detection system is also based on the architecture of FIG. 1 and produces a combined view similar to that shown in FIG. 2. The third embodiment utilizes the same principle of operation as the second embodiment, but differs in the implementation details. Like the second embodiment, a combined image is formed from the combination of a fluorescence image and a reflected image. The difference is that instead of utilizing the excitation light as the source of light for the reflected image, the [0030] light source 10 outputs light expressly for the purpose of producing a reflected image, at a wavelength that is longer than that utilized for the detection of fluorescence. To produce light both at the wavelength required for the excitation of fluorescence and for the purpose of producing a long wavelength reflected image, the excitation filter 26 in the third embodiment has two passbands, one passing short wavelengths for fluorescence excitation (for example 400 nm to 450 nm), and one passing longer wavelengths for the reflected image (for example 630 nm to 700 nm). The filter preferably has very good blocking characteristics in the wavelength region where fluorescence is detected (e.g. less than 10−5 of the incident light should be transmitted between 470 nm and 600 nm). The emission filter 62 passes light in the longer wavelength band which is used for the reflected image (for example 630 nm to 700 nm). This filter 62 should have good blocking of the light in the excitation wavelength band (400 nm to 450 nm in this example). The emission filter 52 must, in addition to the characteristics described for the first embodiment, also have good blocking of light in the band used for the reflect image (for example, in the band 630 nm to 700 nm less than 10−5 of the light should pass the filter). The balance of the system is similar to that of the second embodiment.
  • A fourth embodiment of the skin abnormality detection system according to the present invention is shown in FIG. 3. The fourth embodiment is a viewer that produces a combined, binocular image based on images either from two wavelength bands of emitted autofluorescence light, or from one wavelength band of emitted autofluorescence light and one wavelength band of reflected light. The system described in the fourth embodiment can be obtained by combining two of the systems (i.e., one for each eye) described in one of the first three embodiments to obtain a binocular view. In the example shown in FIG. 3, the [0031] imaging system 100 includes a power source 102, a control module 104 and a light source 106 that supplies light to excite a tissue sample 108 to produce autofluorescence light. A left imaging system 5L provides a superimposed autofluorescence image to a viewer's left eye in the same manner as the system shown in FIG. 1 and described above. An imaging system SR provides a superimposed autofluorescence image for a viewer's right eye in the same manner as the system 5 shown in FIG. 1.
  • A fifth embodiment of the skin abnormality detection system is shown in FIG. 4. The fifth embodiment is an optical system that produces a combined image based on images from two wavelength bands of emitted autofluorescence light. The fifth embodiment is similar to the first embodiment, except that it is intended to be utilized with an instant camera or a digital camera instead of the user's eye. A combined view, similar to that shown in FIG. 2 is recorded and displayed by means of the camera. [0032]
  • As shown in FIG. 4, the fifth embodiment of a skin abnormality detection system according to the present invention is made up of eight major subsystems: a [0033] light source 10 that produces excitation light that will cause the tissue 12 under examination to produce characteristic autofluorescence light, an optical splitter 13 that divides the fluorescence light received from the tissue into two beams, a first optical channel 14 that collects, amplifies, and images the light in one fluorescence wavelength band, a second optical channel IS that collects, amplifies, and images the light in a second fluorescence wavelength band, an optical combiner 16 that combines the images from the two fluorescence optical channels into one and presents the combined image to a digital or instant camera 120 which records the image for viewing, a control module 17, and a power source 18.
  • The [0034] power source 18 could be batteries or the AC line. In the preferred embodiment, battery power is utilized for portability.
  • The [0035] light source 10 provides light of the required characteristics for exciting the tissue fluorescence. It consists of a power supply 21 which is controlled by the control module 17 and which receives electrical power from power source 18. The power supply outputs electrical power of the appropriate characteristics to operate lamp 22. The lamp, which may be a xenon flash lamp, produces a broad spectrum output of visible light (e.g. white light). The light is formed into a beam onto the tissue 12 by reflector 23 and the combination of image forming elements 24 and 25 (e.g. lenses). In addition to forming a beam, a region of collimated light is produced between the two lenses that provides optimal conditions for the placement of an optical band pass filter, excitation filter 26. This filter 26 is designed for incident light to be perpendicular to the filter surface. The excitation filter 16 characteristics are such that the filter passes light of wavelengths utilized to excite fluorescence (typically 400 nm to 450 nm) and blocks light of other wavelengths. It is important that the filter block light in the wavelength bands where fluorescence is detected (i.e. in those bands no more than 1 in 105 of the light from the lamp can pass the filter).
  • Typically, the [0036] lamp 22 is operated in a pulsed mode similar to a camera flash. The advantages of operating in the pulsed mode are that it allows the system to be utilized in an undarkened room and the power required is reduced so battery operation is possible. The intensity and duration of the light (when pulsed) are controlled by the control module 17 as a means of adjusting the brightness of the image as detected by the camera 120.
  • The result of illuminating the [0037] tissue 12 with excitation light is the emission of characteristic autofluorescence light 31 by the tissue. If the excitation light is in the blue, the emitted fluorescence typically spans wavelengths from the green to the red (470 nm to 700 nm). The emitted autofluorescence light 31 is collected and split into two wavelength bands by the optical splitter 13. An image forming element (e.g. lens) 41 in the optical splitter collects the emitted fluorescence light and forms an image of the tissue. The position of the lens 41 can be moved via focus mechanism 44 to focus the image. The light is directed onto a dichroic mirror 42 resulting in the autofluorescence light being split into two wavelength bands. A portion of the light in one wavelength band passes straight through the dichroic mirror and enters the first optical channel 14. The remaining light in the second wavelength band is reflected by the dichroic mirror 42. Typically, the dichroic mirror 42 will pass light having wavelengths less than 570 nm and will reflect light having wavelengths greater than 570 nm. The light reflected by the dichroic mirror is again reflected by a mirror 43 into the second optical channel 15.
  • As mentioned previously, the autofluorescence light that passes straight through the [0038] dichroic mirror 42 enters the first optical channel 14. In this optical channel, autofluorescence light with wavelengths within a defined band is amplified and formed into an image. The optical channel 14 consists of a lens 53, an emission filter 52, an image intensifier 54 with phosphor screen 55 and power supply 56. The lens 53 forms an image at an infinite distance to collimate the light. This results in an optimum location for the emission filter 52 that is designed to filter incident light perpendicular to the filter's surface. Emission filter 52 passes only the autofluorescence light in a band of wavelengths near the maximum in the tissue spectral emission (typically 490 nm to 560 nm). The emission filter preferably has good blocking characteristics for light in the wavelength band utilized for fluorescence excitation. Typically less than 1 in 105 of the excitation light passes the emission filter. The lens 53 forms an image with the autofluorescence light on the input of the image intensifier 54. The image intensifier amplifies the incoming light by a gain determined by a bias voltage supplied by power supply 56. The image intensifier produces an output image on phosphor screen 55. The power supply 56 is controlled by the control module 17. The control module controls the output of the power supply in such a way that the intensifier has the appropriate gain for the light input to the system. The image intensifier phosphor screen 55 has a persistence of at least a few milliseconds, and produces light of a specific wavelength, for example green light mainly in the band 500 nm to 560 nm. The light from the image on the phosphor screen is input to the optical combiner 16.
  • As mentioned previously, the autofluorescence light that is reflected by the dichroic mirror enters into the second [0039] optical channel 15. The second optical channel 15 consists of a lens 63, an emission filter 62, an image intensifier 64 with phosphor screen 65 and power supply 66. The second optical channel 15 is nearly identical to the first optical channel 14 except that the emission filter 62 is different than emission filter 52 in that filter 62 passes light of a different wavelength band (e.g. red light in the band 630 to 750 nm), phosphor screen 65 produces light of different wavelength (e.g. red light in the band 620 nm to 700 nm) than phosphor screen 55, and the gain of the image intensifier 64 as set by controller 71 and power supply 66 may be different than the gain of image intensifier 54. As a result of these differences, the image formed on phosphor screen 65 is from a different autofluorescence band and may be of different brightness. The light from the image on phosphor screen 65 is input to the optical combiner 16.
  • The [0040] optical combiner 16 consists of lens 81, lens 82, dichroic mirror 83, mirror 84 and lens 85. Lens 81 collects light from the image on phosphor screen 55, and in combination with lens 85 relays the image from the phosphor screen to the camera's 120 optical system. Light from the image on phosphor screen 55 in one wavelength band (e.g. green light) passes straight through dichroic mirror 83. The dichroic mirror 83 has, for example, characteristics such that light at wavelengths shorter than 570 nm passes straight through and light at wavelengths longer than 570 nm is reflected. Lens 82 collects light from the second optical channel in a second wavelength band (e.g. red light) from the image on phosphor screen 55. Lens 82, in combination with lens 85 relays the image from phosphor screen 65 to the camera's 120 optical system. The light from phosphor screen 65 is reflected both by mirror 84 and dichroic mirror 83. This results, in combination with the image from phosphor screen 55 that passed straight through the dichroic mirror 83, in the formation of a combined image appropriate for the camera's 120 optical system made up of the images from phosphor screens 55 and 65. The magnifications of lenses 81 and 82 are chosen so that the images from phosphor screens 55 and 65 are the same size at the camera's optical system, even though the optical path lengths are different.
  • The fifth embodiment of a skin abnormality detection system attaches to a digital or [0041] instant camera 120 by means of the camera lens mount 122, or by means of a screw in filter mount on the camera's lens.
  • The control module [0042] 17 consists of a controller 71, and brightness adjustment knob 72. The controller 71 contains circuitry to control the light source power supply and image intensifier power supplies. The shutter button 123 on the camera is activated by the user to start the image acquisition sequence. The camera sends a signal to the controller 71 through the flash synchronization output jack 121 indicating that image acquisition is to start and related to the image brightness. The controller makes use of this signal in controlling the light source power supply and image intensifier power supplies as described below. The brightness adjustment knob 72 is utilized by the user to communicate an adjustable reference point for the brightness of the image to the controller.
  • The brightness of the image as seen by the user is automatically controlled by the [0043] controller 71 based on a combination of measurement of light intensity by the camera light meter, the reference brightness from the brightness adjustment knob 72, and stored image intensifier calibration characteristics. The controller 71 utilizes this information to control the light source intensity and duration, as well as the gain of image intensifiers 54 and 64. The image intensifiers, controlled through their power supplies, are turned on by the controller 71 only during the period that the light source outputs light, plus an additional period while the fluorescence decays (typically 100 microseconds). The camera's shutter is opened for a time much longer than the duration of the light source output (typically {fraction (1/125)} of a second). In order to achieve the best image quality, the control algorithm is designed to operate at the maximum possible light source intensity and pulse duration and minimum intensifier gains. The control algorithm first adjusts the light source intensity and duration to achieve the desired brightness as indicated by the camera light meter. Following this the algorithm adjusts the gain of image intensifier 54 as further required to achieve the desired brightness and then adjusts the gain of image intensifier 64 in such a way that the ratio of the gain of intensifier 54 to the gain of intensifier 64 is constant, based on the calibration parameters. In this way, the color of the combined image is made to be independent of the brightness of the image and independent of the distance between the tissue and the device.
  • A sixth embodiment of the skin abnormality detection system is also based on the embodiment shown in FIG. 4. The architecture of the system is the same as the fifth embodiment and a combined view similar to that shown in FIG. 2 is produced, but a different principle of operation is utilized, necessitating different implementation details. The sixth embodiment is similar to the second embodiment except that the sixth embodiment utilizes a camera to store the image whereas the second embodiment is a viewer. In the fifth embodiment, an image is produced by overlaying images from two different wavelength bands of autofluorescence light. The color of the composite image resulting from the first embodiment depends on the health of the tissue, because the intensity of the autofluorescence light forming one of the images (green) is known to be a strong function of the health of the tissue, whereas the intensity of autofluorescence light forming the second image (red) depends weakly on the health of the tissue. In comparison, in this sixth embodiment a composite image is formed based on one image from the wavelength band of autofluorescence light that is a strong function of the health of the tissue (green), and one image formed from reflected excitation light (blue). As in the fifth embodiment, the color of the combined image depends on the health of the tissue, because the intensity of the autofluorescence light forming one image utilized in the composite varies depending on the health of the tissue, whereas the intensity of the reflected light forming the second image of the composite depends only weakly on the health of the tissue. [0044]
  • The implementation details for the sixth embodiment are different from those of the fifth embodiment in the following ways: The [0045] emission filter 62 for the second optical channel transmits light reflected from the tissue of the same wavelength band as the light emitted by the light source (e.g. 400 nm to 450 nm). In addition, because the reflected light is of much stronger intensity than the fluorescence light utilized in the first embodiment, the image intensifier 64 in the second optical channel 15 of the second embodiment does not need to amplify the light as much and can be of lower quality. Note that, although dichroic mirror 42 is designed to transmit light with shorter wavelengths, for example <570 nm in the first embodiment, there is no need to utilize a different dichroic mirror in this embodiment. This is because typically dichroic mirrors reflect 5% of the incident light in region they transmit, so the dichroic mirror as specified in the fifth embodiment can be utilized to reduce the intensity of the light reflected from the tissue going into the second optical channel 15. Alternatively, a dichroic mirror that transmits in the green and reflects in the blue (e.g. reflects wavelengths<470 nm and transmits wavelengths>470 nm) in conjunction with a neutral density filter or low gain image intensifier can be utilized.
  • Like the sixth embodiment, a seventh embodiment of the skin abnormality detection system is also based on the architecture of FIG. 4 and produces a combined view similar to that shown in FIG. 2. The seventh embodiment utilizes the same principle of operation as the sixth embodiment, but differs in the implementation details. The seventh embodiment is similar to the third embodiment except that the seventh embodiment utilizes a camera to store the image whereas the third embodiment is a viewer. Like the sixth embodiment, a combined image is formed from the combination of a fluorescence image and a reflected image. The difference is that instead of utilizing the excitation light as the source of light for the reflected image, the [0046] light source 10 outputs light expressly for the purpose of producing a reflected image, at a wavelength longer than that utilized for the detection of fluorescence. To produce light both at the wavelength required for the excitation of fluorescence and for the purpose of producing a long wavelength reflected image, the excitation filter 26 in the seventh embodiment light source has two passbands, one passing short wavelengths for fluorescence excitation (for example 400 nm to 450 nm), and one passing longer wavelengths for the reflected image (for example 630 nm to 700 nm). The filter preferably has very good blocking characteristics in the wavelength region where fluorescence is detected (e.g. less than 10−5 of the incident light should be transmitted between 470 nm and 600 nm). The emission filter 62 must also pass light in the longer wavelength band which is used for the reflected image (for example 630 nm to 700 nm). This filter should have good blocking of the light in the excitation wavelength band (400 nm to 450 nm in this example). The emission filter 52 must, in addition to the characteristics described for the fifth embodiment, also have good blocking of light in the band used for the reflect image (for example, in the band 630 nm to 700 nm less than 10−5 of the light should pass the filter). The balance of the system is similar to that of the sixth embodiment.
  • While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention. For example, the present invention is not limited to the detection of skin cancer but can be used to detect other types of lesions that exhibit variations in autofluorescence intensities. The invention may also be utilized in internal organs such as the mouth or during surgical procedures. In addition, the abnormality detection may also be coupled to a scope, such as an endoscope or laproscope, used in the medical field to examine internal tissues and organs. The embodiments described may also be used with tissue where photodynamic agents, which enhance the fluorescence response, have been introduced. Finally, the detection system may be used not only on skin, but also on other surfaces, such as the detection of abnormalities on plants, and the detection of contaminants on non-living surfaces, such as surgical tools or food. It is, therefore, intended that the scope of the invention be determined from the following claims and equivalents thereto. [0047]

Claims (13)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A skin abnormality detection system, comprising:
a light source for producing a concentrated beam of illumination light;
an optical excitation filter that receives the illumination light and creates excitation light by passing light having selected wavelengths, the excitation light generating reflected and fluorescence light when directed onto a surface of interest;
an optical splitter that receives the reflected and fluorescence light from the surface of interest and splits the fluorescence light into two wavelength bands;
a pair of optical channels that receive the light from the optical splitter, each optical channel including:
an optical emission filter for passing light having selected wavelengths;
an optical assembly for forming an image of the surface of interest; and
an image intensifier tube with a long persistence phosphor screen that amplifies the light passed by the optical emission filter and produces an output image with the light passed; and
a passive optical combiner that receives the output image produced in each optical channel and superimposes the output images to create a combined image that is seen by a user.
2. The skin abnormality detection system of claim 1, wherein the passive optical combiner comprises a dichroic mirror that is positioned to direct the output image from each optical channel into an eye of a user.
3. The skin abnormality detection system of claim 1, further comprising a camera positioned to capture the combined output image onto an image sensor.
4. The skin abnormality detection system of claim 1, wherein the image sensor is photographic film.
5. The skin abnormality detection system of claim 1, wherein the image sensor is a digital imaging sensor.
6. The skin abnormality detection system of claim 1, wherein the system includes a pair of optical splitters which direct the light into multiple optical channels and produces a pair of combined output images for a binocular viewing.
7. A skin abnormality detection system comprising:
a light source for producing a beam of illumination light;
an optical excitation filter that receives the illumination light and creates excitation light and reference light, the excitation light generating fluorescence light when directed onto a surface of interest;
an optical splitter that receives the fluorescence light and reflected reference light and directs the fluorescence light and reflected reference light into separate optical channels, each optical channel producing an image of the surface of interest; and
a passive optical combiner that combines the images of the tissue produced with the fluorescence light and the reference light into a single image that can be viewed by a user.
8. The skin abnormality detection system of claim 5, wherein the reference light comprises the excitation light.
9. The skin abnormality detection system of claim 5, wherein the light source produces both excitation light and reference light, and the reference light comprises light having a different wavelength than the excitation light.
10. The skin abnormality detection system of claim 5, wherein the system includes a pair of optical splitters which direct the light into multiple optical channels and produces a pair of combined output images for a binocular viewing.
11. The skin abnormality detection system of claim 5, further comprising a camera positioned to capture the combined output image onto an image sensor.
12. The skin abnormality detection system of claim 9, wherein the image sensor is photographic film.
13. The skin abnormality detection system of claim 9, wherein the image sensor is a digital imaging sensor.
US10/438,551 1999-12-22 2003-05-14 Portable system for detecting skin abnormalities based on characteristic autofluorescence Abandoned US20030206301A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/438,551 US20030206301A1 (en) 1999-12-22 2003-05-14 Portable system for detecting skin abnormalities based on characteristic autofluorescence
US10/830,680 US20040196463A1 (en) 1999-12-22 2004-04-22 Portable system for detecting skin abnormalities based on characteristic autofluorescence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/469,562 US6603552B1 (en) 1999-12-22 1999-12-22 Portable system for detecting skin abnormalities based on characteristic autofluorescence
US10/438,551 US20030206301A1 (en) 1999-12-22 2003-05-14 Portable system for detecting skin abnormalities based on characteristic autofluorescence

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/469,562 Continuation US6603552B1 (en) 1999-12-22 1999-12-22 Portable system for detecting skin abnormalities based on characteristic autofluorescence

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/830,680 Continuation US20040196463A1 (en) 1999-12-22 2004-04-22 Portable system for detecting skin abnormalities based on characteristic autofluorescence

Publications (1)

Publication Number Publication Date
US20030206301A1 true US20030206301A1 (en) 2003-11-06

Family

ID=23864247

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/469,562 Expired - Lifetime US6603552B1 (en) 1999-12-22 1999-12-22 Portable system for detecting skin abnormalities based on characteristic autofluorescence
US10/438,551 Abandoned US20030206301A1 (en) 1999-12-22 2003-05-14 Portable system for detecting skin abnormalities based on characteristic autofluorescence
US10/830,680 Abandoned US20040196463A1 (en) 1999-12-22 2004-04-22 Portable system for detecting skin abnormalities based on characteristic autofluorescence

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/469,562 Expired - Lifetime US6603552B1 (en) 1999-12-22 1999-12-22 Portable system for detecting skin abnormalities based on characteristic autofluorescence

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/830,680 Abandoned US20040196463A1 (en) 1999-12-22 2004-04-22 Portable system for detecting skin abnormalities based on characteristic autofluorescence

Country Status (1)

Country Link
US (3) US6603552B1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060244962A1 (en) * 2005-02-18 2006-11-02 Bio-Chek Llc Pesticide Detector and Method
US20100053312A1 (en) * 2006-11-28 2010-03-04 Olympus Corporation Endoscope apparatus
US9042967B2 (en) 2008-05-20 2015-05-26 University Health Network Device and method for wound imaging and monitoring
CN106226275A (en) * 2016-07-15 2016-12-14 上海交通大学 A kind of based on fingernail autofluorescence as the detection method of biomarker of detection stroke onset and application thereof
US9883804B2 (en) 2012-02-06 2018-02-06 Carl Zeiss Meditec Ag Method and device for examining a biological tissue by analysing fluorescence response to illumination and for treating the tissue
US20180289291A1 (en) * 2017-04-07 2018-10-11 Bunnie Richie Health diagnostic fingerprint scanner
US10438356B2 (en) 2014-07-24 2019-10-08 University Health Network Collection and analysis of data for diagnostic purposes
US11954861B2 (en) 2022-12-30 2024-04-09 University Health Network Systems, devices, and methods for visualization of tissue and collection and analysis of data regarding same

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6603552B1 (en) * 1999-12-22 2003-08-05 Xillix Technologies Corp. Portable system for detecting skin abnormalities based on characteristic autofluorescence
EP1301118B1 (en) 2000-07-14 2006-09-06 Xillix Technologies Corp. Compact fluorescence endoscopy video system
US6678398B2 (en) * 2000-09-18 2004-01-13 Sti Medical Systems, Inc. Dual mode real-time screening and rapid full-area, selective-spectral, remote imaging and analysis device and process
ATE336717T1 (en) 2001-05-17 2006-09-15 Xenogen Corp METHOD AND DEVICE FOR DETERMINING TARGET DEPTH, BRIGHTNESS AND SIZE IN A REGION OF THE BODY
FR2826857B1 (en) * 2001-07-09 2004-03-12 Oreal INSTRUMENT FOR OBSERVING SKIN OR HAIR
US7738032B2 (en) 2001-11-08 2010-06-15 Johnson & Johnson Consumer Companies, Inc. Apparatus for and method of taking and viewing images of the skin
US20060241496A1 (en) * 2002-01-15 2006-10-26 Xillix Technologies Corp. Filter for use with imaging endoscopes
US6899675B2 (en) * 2002-01-15 2005-05-31 Xillix Technologies Corp. Fluorescence endoscopy video systems with no moving parts in the camera
JP4299049B2 (en) * 2003-04-24 2009-07-22 株式会社 日立ディスプレイズ Display device control signal inspection method and inspection apparatus, and display device having this inspection function
US7575321B2 (en) * 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
US7708403B2 (en) * 2003-10-30 2010-05-04 Welch Allyn, Inc. Apparatus and method for diagnosis of optically identifiable ophthalmic conditions
US20090270717A1 (en) 2008-04-25 2009-10-29 Welch Allyn, Inc. Apparatus and method for diagnosis of optically identifiable ophthalmic conditions
CN1898997A (en) * 2003-11-03 2007-01-17 美国芯源系统股份有限公司 Driver for light source having integrated photosensitive elements for driver control
AU2011242140B2 (en) * 2004-04-14 2012-11-29 Led Medical Diagnostics, Inc. Systems and methods for detection of disease including oral scopes and ambient light management systems (ALMS)
US8026942B2 (en) * 2004-10-29 2011-09-27 Johnson & Johnson Consumer Companies, Inc. Skin imaging system with probe
US7460688B2 (en) * 2004-12-09 2008-12-02 Aptina Imaging Corporation System and method for detecting and correcting defective pixels in a digital image sensor
AU2006206334C1 (en) * 2005-01-19 2011-05-19 Dermaspect Llc Devices and methods for identifying and monitoring changes of a suspect area on a patient
DE102005013043A1 (en) * 2005-03-18 2006-09-28 Siemens Ag Mobile fluorescence scanner for molecular signatures has pulse-operated light source to which energy source is connected
US20070002479A1 (en) * 2005-06-29 2007-01-04 Johnson & Johnson Consumer Companies, Inc. Apparatus and method for viewing the skin
US20070004972A1 (en) * 2005-06-29 2007-01-04 Johnson & Johnson Consumer Companies, Inc. Handheld device for determining skin age, proliferation status and photodamage level
US8532736B1 (en) * 2005-07-29 2013-09-10 Hewlett-Packard Development Company, L.P. Apparatus and a method for quantifying properties of skin
US20070122344A1 (en) 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
US8755053B2 (en) 2005-10-14 2014-06-17 Applied Research Associates Nz Limited Method of monitoring a surface feature and apparatus therefor
US20070098596A1 (en) * 2005-10-14 2007-05-03 University Of South Florida Handheld microarray reader
WO2007106624A2 (en) 2006-02-07 2007-09-20 Novadaq Technologies Inc. Near infrared imaging
WO2008011722A1 (en) 2006-07-28 2008-01-31 Novadaq Technologies Inc. System and method for deposition and removal of an optical element on an endoscope objective
US20080161744A1 (en) 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
US9079762B2 (en) 2006-09-22 2015-07-14 Ethicon Endo-Surgery, Inc. Micro-electromechanical device
US7558416B2 (en) * 2006-10-02 2009-07-07 Johnson & Johnson Consumer Companies, Inc. Apparatus and method for measuring photodamage to skin
US7764303B2 (en) * 2006-10-02 2010-07-27 Johnson & Johnson Consumer Companies, Inc. Imaging apparatus and methods for capturing and analyzing digital images of the skin
US8498695B2 (en) 2006-12-22 2013-07-30 Novadaq Technologies Inc. Imaging system with a single color image sensor for simultaneous fluorescence and color video endoscopy
US7713265B2 (en) 2006-12-22 2010-05-11 Ethicon Endo-Surgery, Inc. Apparatus and method for medically treating a tattoo
US8801606B2 (en) 2007-01-09 2014-08-12 Ethicon Endo-Surgery, Inc. Method of in vivo monitoring using an imaging system including scanned beam imaging unit
US8273015B2 (en) 2007-01-09 2012-09-25 Ethicon Endo-Surgery, Inc. Methods for imaging the anatomy with an anatomically secured scanner assembly
US20080177140A1 (en) * 2007-01-23 2008-07-24 Xillix Technologies Corp. Cameras for fluorescence and reflectance imaging
US8216214B2 (en) 2007-03-12 2012-07-10 Ethicon Endo-Surgery, Inc. Power modulation of a scanning beam for imaging, therapy, and/or diagnosis
US7995045B2 (en) 2007-04-13 2011-08-09 Ethicon Endo-Surgery, Inc. Combined SBI and conventional image processor
US8626271B2 (en) 2007-04-13 2014-01-07 Ethicon Endo-Surgery, Inc. System and method using fluorescence to examine within a patient's anatomy
US8160678B2 (en) 2007-06-18 2012-04-17 Ethicon Endo-Surgery, Inc. Methods and devices for repairing damaged or diseased tissue using a scanning beam assembly
US7982776B2 (en) 2007-07-13 2011-07-19 Ethicon Endo-Surgery, Inc. SBI motion artifact removal apparatus and method
US9125552B2 (en) 2007-07-31 2015-09-08 Ethicon Endo-Surgery, Inc. Optical scanning module and means for attaching the module to medical instruments for introducing the module into the anatomy
US7983739B2 (en) 2007-08-27 2011-07-19 Ethicon Endo-Surgery, Inc. Position tracking and control for a scanning assembly
US7925333B2 (en) 2007-08-28 2011-04-12 Ethicon Endo-Surgery, Inc. Medical device including scanned beam unit with operational control features
US20090124854A1 (en) * 2007-11-09 2009-05-14 Fujifilm Corporation Image capturing device and image capturing system
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
EP2268194B1 (en) 2008-03-18 2016-08-31 Novadaq Technologies Inc. Imaging system for combined full-color reflectance and near-infrared imaging
US8050520B2 (en) 2008-03-27 2011-11-01 Ethicon Endo-Surgery, Inc. Method for creating a pixel image from sampled data of a scanned beam imager
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
US8332014B2 (en) 2008-04-25 2012-12-11 Ethicon Endo-Surgery, Inc. Scanned beam device and method using same which measures the reflectance of patient tissue
WO2009135178A2 (en) 2008-05-02 2009-11-05 Flower Robert W Methods for production and use of substance-loaded erythrocytes (s-les) for observation and treatment of microvascular hemodynamics
US8767049B2 (en) * 2008-07-21 2014-07-01 University Of South Carolina Membrane-deformation mapping technique
EP2318831A4 (en) * 2008-07-22 2014-03-26 Jaafar Tindi Handheld apparatus to determine the viability of a biological tissue
US9844333B2 (en) * 2009-03-24 2017-12-19 International Business Machines Corporation Remote delivery and monitoring of health care
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US8606345B2 (en) * 2009-08-31 2013-12-10 Gsm Of Kansas, Inc. Medical dual lens camera for documentation of dermatological conditions with laser distance measuring
JP5721940B2 (en) * 2009-11-04 2015-05-20 オリンパス株式会社 Optical spectrum detection method
BR112013022997A2 (en) 2011-03-08 2018-07-03 Novadaq Technologies Inc. full spectrum led illuminator.
US8900126B2 (en) 2011-03-23 2014-12-02 United Sciences, Llc Optical scanning device
JP2013034569A (en) * 2011-08-05 2013-02-21 Gc Corp Intraoral examination device and method for operating the same
US9179844B2 (en) 2011-11-28 2015-11-10 Aranz Healthcare Limited Handheld skin measuring or monitoring device
US8900125B2 (en) 2012-03-12 2014-12-02 United Sciences, Llc Otoscanning with 3D modeling
JP6028096B2 (en) 2012-06-21 2016-11-16 ノバダック テクノロジーズ インコーポレイテッド Angiography and perfusion quantification and analysis techniques
US10178971B2 (en) * 2013-04-18 2019-01-15 Koninklijke Philips N.V. Acquiring cervical images
US10602918B2 (en) 2013-12-31 2020-03-31 Karl Storz Imaging, Inc. Switching between white light imaging and excitation light imaging leaving last video frame displayed
US10602917B2 (en) 2013-12-31 2020-03-31 Karl Storz Imaging, Inc. Switching between white light imaging and excitation light imaging leaving last video frame displayed
KR20170067803A (en) 2014-09-29 2017-06-16 노바다크 테크놀러지즈 인코포레이티드 Imaging a target fluorophore in a biological material in the presence of autofluorescence
WO2016055837A1 (en) 2014-10-09 2016-04-14 Novadaq Technologies Inc. Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
DE102015011429B9 (en) * 2015-09-01 2020-01-09 Carl Zeiss Meditec Ag Optical filter system and fluorescence observation system
CN108289723B (en) 2015-11-13 2021-07-06 史赛克欧洲运营有限公司 System and method for illumination and imaging of an object
EP3408654B1 (en) 2016-01-26 2022-08-03 Stryker European Operations Limited Fluorescence imaging system and method for fluorescence imaging
US10293122B2 (en) 2016-03-17 2019-05-21 Novadaq Technologies ULC Endoluminal introducer with contamination avoidance
USD916294S1 (en) 2016-04-28 2021-04-13 Stryker European Operations Limited Illumination and imaging device
US10013527B2 (en) 2016-05-02 2018-07-03 Aranz Healthcare Limited Automatically assessing an anatomical surface feature and securely managing information related to the same
EP3469420A4 (en) 2016-06-14 2020-02-12 Novadaq Technologies ULC Methods and systems for adaptive imaging for low light signal enhancement in medical visualization
US11116407B2 (en) 2016-11-17 2021-09-14 Aranz Healthcare Limited Anatomical surface assessment methods, devices and systems
WO2018145193A1 (en) 2017-02-10 2018-08-16 Novadaq Technologies ULC Open-field handheld fluorescence imaging systems and methods
EP3606410B1 (en) 2017-04-04 2022-11-02 Aranz Healthcare Limited Anatomical surface assessment methods, devices and systems
CN109363768A (en) * 2018-10-10 2019-02-22 南京诺源医疗器械有限公司 785nm wavelength light source near-infrared fluorescence imaging surgery guides system

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200801A (en) * 1979-03-28 1980-04-29 The United States Of America As Represented By The United States Department Of Energy Portable spotter for fluorescent contaminants on surfaces
US4532918A (en) * 1983-10-07 1985-08-06 Welch Allyn Inc. Endoscope signal level control
US4556057A (en) * 1982-08-31 1985-12-03 Hamamatsu Tv Co., Ltd. Cancer diagnosis device utilizing laser beam pulses
US4786813A (en) * 1984-10-22 1988-11-22 Hightech Network Sci Ab Fluorescence imaging system
US4821117A (en) * 1986-11-12 1989-04-11 Kabushiki Kaisha Toshiba Endoscopic system for producing fluorescent and visible images
US4930516A (en) * 1985-11-13 1990-06-05 Alfano Robert R Method for detecting cancerous tissue using visible native luminescence
US5134662A (en) * 1985-11-04 1992-07-28 Cell Analysis Systems, Inc. Dual color camera microscope and methodology for cell staining and analysis
US5165079A (en) * 1989-02-02 1992-11-17 Linotype-Hell Ag Optical color-splitter arrangement
US5214503A (en) * 1992-01-31 1993-05-25 The United States Of America As Represented By The Secretary Of The Army Color night vision camera system
US5225883A (en) * 1991-06-05 1993-07-06 The Babcock & Wilcox Company Video temperature monitor
US5255087A (en) * 1986-11-29 1993-10-19 Olympus Optical Co., Ltd. Imaging apparatus and endoscope apparatus using the same
US5365057A (en) * 1993-07-02 1994-11-15 Litton Systems, Inc. Light-weight night vision device
US5371355A (en) * 1993-07-30 1994-12-06 Litton Systems, Inc. Night vision device with separable modular image intensifier assembly
US5377686A (en) * 1991-10-11 1995-01-03 The University Of Connecticut Apparatus for detecting leakage from vascular tissue
US5419323A (en) * 1988-12-21 1995-05-30 Massachusetts Institute Of Technology Method for laser induced fluorescence of tissue
US5420628A (en) * 1990-01-16 1995-05-30 Research Development Foundation Video densitometer with determination of color composition
US5421337A (en) * 1989-04-14 1995-06-06 Massachusetts Institute Of Technology Spectral diagnosis of diseased tissue
US5424841A (en) * 1993-05-28 1995-06-13 Molecular Dynamics Apparatus for measuring spatial distribution of fluorescence on a substrate
US5430476A (en) * 1992-06-24 1995-07-04 Richard Wolf Gmbh Device for supplying light to endoscopes
US5507287A (en) * 1991-05-08 1996-04-16 Xillix Technologies Corporation Endoscopic imaging system for diseased tissue
US5590660A (en) * 1994-03-28 1997-01-07 Xillix Technologies Corp. Apparatus and method for imaging diseased tissue using integrated autofluorescence
US5647368A (en) * 1996-02-28 1997-07-15 Xillix Technologies Corp. Imaging system for detecting diseased tissue using native fluorsecence in the gastrointestinal and respiratory tract
US5772580A (en) * 1995-03-03 1998-06-30 Asahi Kogaku Kogyo Kabushiki Kaisha Biological fluorescence diagnostic apparatus with distinct pickup cameras
US6008889A (en) * 1997-04-16 1999-12-28 Zeng; Haishan Spectrometer system for diagnosis of skin disease
US6021344A (en) * 1996-12-04 2000-02-01 Derma Technologies, Inc. Fluorescence scope system for dermatologic diagnosis
US6148227A (en) * 1998-01-07 2000-11-14 Richard Wolf Gmbh Diagnosis apparatus for the picture providing recording of fluorescing biological tissue regions
US6603552B1 (en) * 1999-12-22 2003-08-05 Xillix Technologies Corp. Portable system for detecting skin abnormalities based on characteristic autofluorescence

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3487933B2 (en) 1993-12-03 2004-01-19 オリンパス株式会社 Fluorescence observation device
JPH07155291A (en) 1993-12-03 1995-06-20 Olympus Optical Co Ltd Fluorescence observation apparatus
JPH07155290A (en) 1993-12-03 1995-06-20 Olympus Optical Co Ltd Endoscope apparatus
JP3194660B2 (en) 1993-12-03 2001-07-30 オリンパス光学工業株式会社 Fluorescence observation device
JP3285265B2 (en) 1993-12-03 2002-05-27 オリンパス光学工業株式会社 Fluorescence observation device
JP3283128B2 (en) 1993-12-03 2002-05-20 オリンパス光学工業株式会社 Fluorescence observation endoscope device
JPH07250804A (en) 1994-03-15 1995-10-03 Olympus Optical Co Ltd Fluorescence observer
JPH07250812A (en) 1994-03-15 1995-10-03 Olympus Optical Co Ltd Fluorescence diagnosing apparatus
JPH08224240A (en) 1995-02-22 1996-09-03 Olympus Optical Co Ltd Fluorescent diagnosing device
JPH08224208A (en) 1995-02-22 1996-09-03 Olympus Optical Co Ltd Fluorescence observing endoscope device
JP3560671B2 (en) 1995-02-23 2004-09-02 オリンパス株式会社 Fluorescence observation device
JP3177635B2 (en) 1996-09-30 2001-06-18 株式会社応用光電研究室 Frequency standard and selection standard frequency generation method
JP3713347B2 (en) 1996-11-25 2005-11-09 オリンパス株式会社 Fluorescence endoscope device
JP3771985B2 (en) 1997-01-20 2006-05-10 オリンパス株式会社 Fluorescence observation endoscope device
JPH11155812A (en) 1997-12-02 1999-06-15 Olympus Optical Co Ltd Fluorescent observation device
EP1148810B1 (en) 1999-01-26 2005-11-16 Newton Laboratories, Inc. Autofluorescence imaging system for endoscopy

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200801A (en) * 1979-03-28 1980-04-29 The United States Of America As Represented By The United States Department Of Energy Portable spotter for fluorescent contaminants on surfaces
US4556057A (en) * 1982-08-31 1985-12-03 Hamamatsu Tv Co., Ltd. Cancer diagnosis device utilizing laser beam pulses
US4532918A (en) * 1983-10-07 1985-08-06 Welch Allyn Inc. Endoscope signal level control
US4786813A (en) * 1984-10-22 1988-11-22 Hightech Network Sci Ab Fluorescence imaging system
US5134662A (en) * 1985-11-04 1992-07-28 Cell Analysis Systems, Inc. Dual color camera microscope and methodology for cell staining and analysis
US4930516A (en) * 1985-11-13 1990-06-05 Alfano Robert R Method for detecting cancerous tissue using visible native luminescence
US4930516B1 (en) * 1985-11-13 1998-08-04 Laser Diagnostic Instr Inc Method for detecting cancerous tissue using visible native luminescence
US4821117A (en) * 1986-11-12 1989-04-11 Kabushiki Kaisha Toshiba Endoscopic system for producing fluorescent and visible images
US5255087A (en) * 1986-11-29 1993-10-19 Olympus Optical Co., Ltd. Imaging apparatus and endoscope apparatus using the same
US5419323A (en) * 1988-12-21 1995-05-30 Massachusetts Institute Of Technology Method for laser induced fluorescence of tissue
US5165079A (en) * 1989-02-02 1992-11-17 Linotype-Hell Ag Optical color-splitter arrangement
US5421337A (en) * 1989-04-14 1995-06-06 Massachusetts Institute Of Technology Spectral diagnosis of diseased tissue
US5420628A (en) * 1990-01-16 1995-05-30 Research Development Foundation Video densitometer with determination of color composition
US5507287A (en) * 1991-05-08 1996-04-16 Xillix Technologies Corporation Endoscopic imaging system for diseased tissue
US5225883A (en) * 1991-06-05 1993-07-06 The Babcock & Wilcox Company Video temperature monitor
US5377686A (en) * 1991-10-11 1995-01-03 The University Of Connecticut Apparatus for detecting leakage from vascular tissue
US5214503A (en) * 1992-01-31 1993-05-25 The United States Of America As Represented By The Secretary Of The Army Color night vision camera system
US5430476A (en) * 1992-06-24 1995-07-04 Richard Wolf Gmbh Device for supplying light to endoscopes
US5424841A (en) * 1993-05-28 1995-06-13 Molecular Dynamics Apparatus for measuring spatial distribution of fluorescence on a substrate
US5365057A (en) * 1993-07-02 1994-11-15 Litton Systems, Inc. Light-weight night vision device
US5371355A (en) * 1993-07-30 1994-12-06 Litton Systems, Inc. Night vision device with separable modular image intensifier assembly
US5590660A (en) * 1994-03-28 1997-01-07 Xillix Technologies Corp. Apparatus and method for imaging diseased tissue using integrated autofluorescence
US5827190A (en) * 1994-03-28 1998-10-27 Xillix Technologies Corp. Endoscope having an integrated CCD sensor
US5772580A (en) * 1995-03-03 1998-06-30 Asahi Kogaku Kogyo Kabushiki Kaisha Biological fluorescence diagnostic apparatus with distinct pickup cameras
US5647368A (en) * 1996-02-28 1997-07-15 Xillix Technologies Corp. Imaging system for detecting diseased tissue using native fluorsecence in the gastrointestinal and respiratory tract
US6021344A (en) * 1996-12-04 2000-02-01 Derma Technologies, Inc. Fluorescence scope system for dermatologic diagnosis
US6008889A (en) * 1997-04-16 1999-12-28 Zeng; Haishan Spectrometer system for diagnosis of skin disease
US6069689A (en) * 1997-04-16 2000-05-30 Derma Technologies, Inc. Apparatus and methods relating to optical systems for diagnosis of skin diseases
US6148227A (en) * 1998-01-07 2000-11-14 Richard Wolf Gmbh Diagnosis apparatus for the picture providing recording of fluorescing biological tissue regions
US6603552B1 (en) * 1999-12-22 2003-08-05 Xillix Technologies Corp. Portable system for detecting skin abnormalities based on characteristic autofluorescence

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304741B2 (en) * 2005-02-18 2007-12-04 Bio-Chek Llc Pesticide detector and method
US20060244962A1 (en) * 2005-02-18 2006-11-02 Bio-Chek Llc Pesticide Detector and Method
US20100053312A1 (en) * 2006-11-28 2010-03-04 Olympus Corporation Endoscope apparatus
US8773521B2 (en) * 2006-11-28 2014-07-08 Olympus Corporation Endoscope apparatus
US11154198B2 (en) 2008-05-20 2021-10-26 University Health Network Method and system for imaging and collection of data for diagnostic purposes
US9042967B2 (en) 2008-05-20 2015-05-26 University Health Network Device and method for wound imaging and monitoring
US11375898B2 (en) 2008-05-20 2022-07-05 University Health Network Method and system with spectral filtering and thermal mapping for imaging and collection of data for diagnostic purposes from bacteria
US11284800B2 (en) 2008-05-20 2022-03-29 University Health Network Devices, methods, and systems for fluorescence-based endoscopic imaging and collection of data with optical filters with corresponding discrete spectral bandwidth
US9883804B2 (en) 2012-02-06 2018-02-06 Carl Zeiss Meditec Ag Method and device for examining a biological tissue by analysing fluorescence response to illumination and for treating the tissue
US10973411B2 (en) 2012-02-06 2021-04-13 Carl Zeiss Meditec Ag Method and device for examining a biological tissue by analysing fluorescence response to illumination and for treating the tissue
US10438356B2 (en) 2014-07-24 2019-10-08 University Health Network Collection and analysis of data for diagnostic purposes
US11676276B2 (en) 2014-07-24 2023-06-13 University Health Network Collection and analysis of data for diagnostic purposes
CN106226275A (en) * 2016-07-15 2016-12-14 上海交通大学 A kind of based on fingernail autofluorescence as the detection method of biomarker of detection stroke onset and application thereof
US20180289291A1 (en) * 2017-04-07 2018-10-11 Bunnie Richie Health diagnostic fingerprint scanner
US11954861B2 (en) 2022-12-30 2024-04-09 University Health Network Systems, devices, and methods for visualization of tissue and collection and analysis of data regarding same

Also Published As

Publication number Publication date
US6603552B1 (en) 2003-08-05
US20040196463A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
US6603552B1 (en) Portable system for detecting skin abnormalities based on characteristic autofluorescence
US6422994B1 (en) Fluorescent diagnostic system and method providing color discrimination enhancement
US5647368A (en) Imaging system for detecting diseased tissue using native fluorsecence in the gastrointestinal and respiratory tract
US20190082963A1 (en) Compact fluorescence endoscopy video system
US10182709B2 (en) Filter for use with imaging endoscopes
EP1239771B1 (en) Portable system for detecting skin abnormalities
JP3683271B2 (en) Apparatus and method for imaging an image of diseased tissue using integrated internal fluorescence
JP3236085B2 (en) Endoscope device
US20030135092A1 (en) Fluorescence endoscopy video systems with no moving parts in the camera
WO1999001749A1 (en) Fluorescence imaging system
JPH0654792A (en) Image pickup device
JP2001128925A (en) Method and device for fluorescent character display
JP2005312979A (en) Imaging device
JP2002330919A (en) Endoscope system for fluorescent observation

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION